3rd plenary session! #1722 Defining safe HCQ levels in SLE: whole-blood 750-1150ng/mL= therapeutic range; >1150ng/mL ➡️ ~2× toxicity risk; <750ng/mL ➡️ higher flare risk CKD ≥3 increases odds of supratherapeutic levels New era of precision monitoring in SLE? @RheumNow #ACR25

Plenary 3, HCQ blood levels in SLE HCQ level > 1150: 1.9x risk of HCQ toxicity HCQ level < 750: 1.4x risk of active SLE HCQ dose < 5mg/kg: 1.9x risk active SLE My take home? Blindly reducing dose to <5mg/kg is BAD; use levels instead! @RheumNow #ACRBest #ACR25 Abstr1722 https://t.co/UCBPAKAyon

• https://x.com/EBRheum/status/1983156804226777296/photo/1
• https://x.com/EBRheum/status/1983156804226777296/photo/1

#ACR25 Please find my video interview with Dr Kate Rochlin on a novel Bi-specific T-cell engager (BiTE) in development which binds to pan-gamma delta T-cell instead of CD3 to minimise risk of cytokine release syndrome side effect. Abstr#1535 @RheumNow https://t.co/MOmUm41cyA https://t.co/TgIUGgWGw5

• The Power of Gamma Delta T Cell for Autoimmunity
• https://x.com/Yuz6Yusof/status/1983153161717330337/photo/1

PET and histologic discordance in aortitis Of 5 aortitis patients who had PET/CT prior to aortic surgery with path, only 1 showed concordance (neg PET, neg biopsy) 4/5 patients had inflammatory biopsy with neg PET Small # but PET is not perfect! @RheumNow #ACR25 Abst 1620

Abstract 1718: Immune checkpoint inhibitors (ICI) in pre-existing #SLE Compared to non-SLE pts, those with SLE receiving ICIs had: 🔹 ↑ risk of thrombocytopenia & pancytopenia 🔹 No significant difference in all-cause mortality @RheumNow #ACR25 https://t.co/N1iOvxbsAZ

• https://x.com/AkhilSoodMD/status/1982921999350718964/photo/1

IL-5 agents may in fact work for severe EGPA manifestations Although severe pt were excluded from enrollment in MANDARA, post-hoc and OLE data suggest development of severe manifestations is rare in benra treated patients @RheumNow #ACR25 https://t.co/slUpAT9mWo

• https://x.com/Dr_Brian_MD/status/1982922182314561831/photo/1

ANCA status does not inform IL-5 agent response in EGPA patients Terrier et al. analyzed the OLE of MANDARA and compared ANCA+ and ANCA- subgroups: - similar rates of remission - similar rates of GC withdrawal - comparable relapse rates @RheumNow #ACR25 Abst 1594

Abstract 1657: Can LLMs track medication history? GPT-4 outperformed most LLMs in identifying TNFi start/stop events and reasons for switch. 💊 Common reasons for TNFi switching: lack of effectiveness, adverse events, and insurance/cost barriers. @RheumNow #ACR25 https://t.co/5FUR9tBoyu

• https://x.com/AkhilSoodMD/status/1982909416413507694/photo/1

#ACR25 Abstr#1532 “The more the merrier” or “Too many cooks..” Preliminary data of CTA313, dual CD19-BCMA CAR-T in 15 #SLE pts showed deep depletion & good response. Global study is planned. Will have to keep on eye on safety (G3 herpes zoster, pneumonia & neutropenia) @RheumNow https://t.co/0KQa9K6bYB

• https://x.com/Yuz6Yusof/status/1982900831436615909/photo/1